Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 3/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802880 | 0.79 | CDK1 (0.39) | SLC2A1ADRA1ACDK1CCNB1CCNB2 | |
| SCHEMBL1799236 | 0.74 | CDK1 (0.36) | CDK1CCNB1CCNB2CCNB3GSK3B | |
| SCHEMBL1796421 | 0.69 | SLC2A1 (0.43) | SLC2A1 | |
| SCHEMBL1800468 | 0.66 | PTGDR2 (0.37) | — | |
| SCHEMBL1800464 | 0.64 | HTR6 (0.33) | — | |
| SCHEMBL1150164 | 0.63 | SLC2A1 (0.47) | SLC2A1 | |
| SCHEMBL29606686 | 0.63 | HTR6 (0.51) | — | |
| SCHEMBL2752494 | 0.61 | BRD4 (0.42) | — | |
| SCHEMBL1723806 | 0.61 | PARP1 (0.40) | SLC2A1 | |
| 1-Methylcamalexin SCHEMBL29934287 | 0.61 | KDR (0.51) | CDK1CCNB1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | SLC2A1 4062/4885ADRA1A 2635/4885ADRA1D 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.